Vericel (NASDAQ:VCEL) Issues Quarterly Earnings Results

Vericel (NASDAQ:VCEL) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12, Zacks reports. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.02) EPS. Vericel updated its FY 2025 guidance to EPS.

Vericel Stock Up 4.2%

NASDAQ:VCEL traded up $1.55 on Thursday, reaching $38.75. The stock had a trading volume of 1,892,134 shares, compared to its average volume of 567,276. The company has a market capitalization of $1.96 billion, a P/E ratio of 322.94 and a beta of 1.41. Vericel has a 1-year low of $29.24 and a 1-year high of $63.00. The stock has a fifty day moving average price of $33.73 and a 200-day moving average price of $37.74.

Analyst Ratings Changes

VCEL has been the subject of several research reports. BTIG Research cut Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Canaccord Genuity Group dropped their price objective on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 1st. Zacks Research upgraded shares of Vericel from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Truist Financial lowered their target price on shares of Vericel from $46.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Vericel in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $58.40.

Institutional Investors Weigh In On Vericel

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in Vericel in the 1st quarter valued at $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Vericel by 6.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock valued at $1,403,000 after buying an additional 1,847 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Vericel by 13.6% in the first quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 44,333 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Vericel by 9.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock worth $5,490,000 after buying an additional 10,191 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in Vericel by 5.1% during the 2nd quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock worth $11,797,000 after buying an additional 13,422 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.